Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Stock Information for Harrow Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Harrow Inc Com

Harrow Relaunches TRIESENCE®
Harrow Announces Nashville Expansion
Harrow to Present at Three Investor Conferences in September in New York
Harrow Announces Second Quarter 2024 Financial Results
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
Harrow to Attend 2024 ASRS Annual Meeting
Harrow Enters into 340B Prime Vendor Program Contract with Apexus(TM) for IHEEZO® and Other Key Harrow Products
Harrow Provides TRIESENCE® Relaunch Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.